11月24日 - ** 制药商默克MRK.N股价盘前上涨2.3%，报100.15美元
** 富国银行将默克股票评级从 "等权重 "上调至 "增持"；将目标价从90美元上调至125美元
** 券商称最近的业务发展和管线进展降低了Keytruda失去独家代理权后收入断崖的风险；认为增长将持续到2030年代初
** 注意到MRK在过去3-6个月中增加或降低了超过200亿美元的未调整峰值销售机会的风险，包括Cidara CDTX.O的收购和Cadence的积极数据
** 预计在未来 12-18 个月内，肿瘤、艾滋病和心血管项目将出现催化剂；管线可支持超过 500 亿美元的未调整峰值销售额
** 截至上一交易日收盘，MRK 股价累计下跌 1.73
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.